Phase 3 NeoCol trial in 248 patients with locally advanced colon cancer: neoadjuvant capecitabine and oxaliplatin did not improve 3-year DFS vs upfront surgery (83% vs 87%; P=.36), though fewer met criteria for adjuvant chemotherapy (59% vs 73%).
RCTn = 250
Jensen et al. Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical Trial